Superior Genomics
Norway, US · Founded 2023
Superior Genomics is an early-stage health technology company developing diagnostic blood tests that distinguish depressive symptoms as either Bipolar Disorder or Major Depressive Disorder, based on gene expression bioprofiles found in blood. It aims to provide objective diagnostic tools for mental health disorders in clinical settings.
Founders & leadership
JP
John Prista FreshleyNamed on SEC filing
DV
David Van HollaDr.
Reported raises · per SEC filings
Form D private placements$507.5K disclosed across 1 round · 2026
▶$507.5KraisedAug 2026 · 14 investors · Other TechnologyRule 506(b)
▶$507.5KraisedAug 2026 · 14 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- David Van HollaExecutive Officer, Director
- John Prista FreshleyDirector
- Offering amount
- $1.5M
- Amount sold
- $507.5K
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Superior Genomics do?
- Superior Genomics is an early-stage health technology company developing diagnostic blood tests that distinguish depressive symptoms as either Bipolar Disorder or Major Depressive Disorder, based on gene expression bioprofiles found in blood. It aims to provide objective diagnostic tools for mental health disorders in clinical settings.
- How much funding has Superior Genomics raised?
- Superior Genomics has disclosed $507.5K raised across 1 round.
- Where is Superior Genomics headquartered?
- Superior Genomics is headquartered in Norway, US.